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Introduction
The six-transmembrane epithelial antigen of prostate (STEAP) protein was identified in advanced prostate cancer [1] . STEAP1 is highly expressed in human prostate cancer and is up-regulated in various cancers, including lung, bladder, colon, ovarian, and Ewing cancers [1, 2, 3] . Immunohistochemical analysis of clinical specimens demonstrates significant STEAP1 expression at the cell-cell junctions of the secretory epithelium of prostate and prostate cancer cells [1] . Little to no staining was detected at the plasma membranes of normal non-prostate human tissues, except for bladder tissue, which expressed low levels of STEAP1 at the cell membrane. Its cell-surface localization, together with its six-transmembrane topology, suggests STEAP1 may function as a channel/transporter protein in cell-cell junctions [1] . Given its increased expression in cancer tissues, STEAP1 could be a promising target for T-cell based or antibody immunotherapy. In prostate cancers, STEAP1-specific cytotoxic T lymphocytes (CTLs) were found to inhibit the growth of transplantable prostate tumor cells in murine models [2, 4, 5] . An immunization with recombinant DNA or modified vaccinia virus Ankara vector delivering STEAP1 antigen inhibited prostate cancer progression in a murine subcutaneous syngeneic tumor model [6] . Targeting STEAP1 appeared also useful for Tcell based immunotherapy in renal and bladder cancers [7] . Finally, STEAP1 was also described as an attractive target for antibody therapy in multiple solid tumors including prostate, renal and bladder cancers [3] .
In this report, we have investigated the expression of STEAP1 gene in 40 human tumor types -brain, epithelial, lymphoid -as well as in their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray inserm-00760262, version 1 -3 Dec 2012 database.
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Materials and Methods
Databases and gene expression data STEAP1 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database (http://www.oncomine.org) [8] , Amazonia database (http:// amazonia.montp.inserm.fr/) [9] , or ITTACA database (Integrated Tumor Transcriptome Array and Clinical data Analysis, http://bioinfoout.curie.fr/ittaca/) [10] . Comparison of STEAP1 expression between samples was performed only when gene expression data were from a same study, using the same methodology. Gene expression profiling (GEP) data are either two channel ratio data (from cDNA microarrays) or single channel intensity data (from Affymetrix microarrays).
All data were log transformed, median centered per array, and the standard deviation was normalized to one per array [11] .
MMCs were purified from 206 patients with newly-diagnosed MM after written informed consent was given at the University hospitals of Heidelberg (Germany) or Montpellier (France). The study was approved by the ethics boards of Heidelberg and Montpellier Universities. After Ficoll-density gradient centrifugation, plasma cells were purified using anti-CD138 MACS microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Microarray experiments were performed in DNA microarray platform of the Institute of lines was also investigated for STEAP1 expression (accession number GSE36133).
Patient cohorts were described in supplementary appendix 1.
Statistical analysis
Statistical comparisons were done with student t-test. Gene expression data of MM patients were normalized with the MAS5 algorithm and analyzed with our bioinformatics platforms: RAGE (http://rage.montp.inserm.fr/) [12] and Amazonia (http://amazonia.montp.inserm.fr/) [9] . The prognostic value of STEAP1 gene expression signal was determined using the MaxStat R function in R software (http://www.rproject.org). The statistical significance of differences in overall survival between groups of patients was calculated by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. Survival curves were plotted using the Kaplan-Meier method. All these analyses have been done with R.2.10.1 (http://www.rproject.org/) and bioconductor version 2.5.
Western blot analysis inserm-00760262, version 1 -3 Dec 2012
Cells were lysed in 10 mM Tris-HCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate (NaPPi), 1% triton X-100, 5 µM ZnCl 2 , 100 µM Na 3 VO4, 1 mM DTT, 20 mM β-glycerophosphate, 20 mM p-nitrophenolphosphate (PNPP), 20 µg/ml aprotinin, 2.5 µg/ml leupeptin, 0.5 mM PMSF, 0.5 mM benzamidine, 5 µg/ml pepstatin, and 50 nM okadaic acid. Lysates were resolved on 12% sodium dodecyl sulfate-polyacrylamide by gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane 
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Results and discussion STEAP1 expression was investigated in 40 tumor types including 36 solid tumors and 4 hematological malignancies and in the corresponding normal tissues (Table 1 and Figure 1 ). Overexpression of STEAP1 was found in glioblastoma compared to normal brain (P = 4.5E-5) [13] ; in esophageal cancer compared to normal esophagus in two independent studies (P = 4.5E-5, 7.4E-9) [14, 15] ; in pancreatic carcinoma compared to normal pancreas in three independent studies (P = 1.6E-13, 6.1E-5, .007) [16, 17, 18] ; in prostate carcinoma compared to normal prostate in three independent studies (P =
1.8E-6, 2.4E-4, 9.6E-4) [19, 20, 21] ; in head and neck cancer compared to normal counterpart in three independent studies (P = 2.3E-18, 1.1E-5, .001) [22, 23, 24] ; in lung carcinoma compared to normal lung in six independent studies (P = 1.5E-4, P = 2.3E-4, P = 3.9E-4, P = 5.1E-16, P = 8.8E-16, P = 4.5E-5, P = 7.8E-5 and P = .005) [25, 26, 27, 28, 29, 30] . Overexpression of STEAP1 was also found in primary effusion lymphoma compared to normal B cells (P = 3.1E-5) [31] and in various leukemia compared to normal bone marrow: T-cell acute lymphoblastic leukemia (P = 5.6E-9) [32] , acute myeloid leukemia (P = 5.6E-9) [32] ; B-cell acute lymphoblastic leukemia (P = 8.3E-12) [32] ; and T-cell prolymphocytic leukemia (P = 5.1E-7) [33] .
Given that STEAP1 was shown to be expressed in prostate cancer metastases [3] and to be associated with invasive behaviour of Ewing tumors [34] , an association between STEAP1 expression and tumor progression and patients' survival was investigated. A high STEAP1 expression was significantly associated with a reduced overall survival in patients with colorectal cancer (n=177; P = .02), with diffuse large B cell lymphoma (n=414; P = .008), with acute myeloid leukemia (n=79; P = .0005), or with multiple myeloma (MM) (n=206 P = .01 and n=345; P =.02) (Figure 2 ). Patients were split into inserm-00760262, version 1 -3 Dec 2012
two groups using Maxstat R function [35] according to STEAP1 expression. In patients with colorectal cancer, a maximum difference in overall survival (OS) was obtained splitting patients in a high-risk group of 26% patients (STEAP1 signal > 1155 (unlogged GEP data)) with a 50 months median OS and a low risk group of 74% patients (STEAP1 signal ≤ -1155) with 133 months median OS (Figure 2 ). In patients with DLBCL, a maximum difference in overall survival (OS) was obtained splitting patients in a high-risk group of 67.6% (STEAP1 signal > 164 (unlogged GEP data)) with a 73 months median OS and a low risk group of 32.4% patients (STEAP1 signal ≤ 164) with not reached median OS (Figure 2 ). In patients with cytogenetically normal AML, a maximum difference in overall survival (OS) was obtained splitting patients in a high-risk group of 10.1% (STEAP1 signal > 6.07 (log transformed GEP data)) with a 4 months median OS and a low risk group of 89.9% patients (STEAP1 signal ≤ 6.07) with 20 months median OS ( Figure 2 ). In patients with MM, a maximum difference in overall survival (OS) was obtained splitting patients in a high-risk group of 31% with a 74 and 67 months median OS respectively in two independent cohorts of patients and a low risk group of 69% patients with not reached median OS (Figure 2 ). Furthermore, STEAP1 is significantly overexpressed in malignant plasma cells compared to normal bone marrow plasma cells and in tumor cells of patients with AML compared to normal hematopoietic stem cells (Supplementary Figure 1) . In MM, seven molecular groups of tumor cells have been identified in previously-untreated patients [36] , and STEAP1 was significantly overexpressed in the proliferation group and in the groups associated with Cyclin D1 or MMSET translocations (Figure 3) , two of them (proliferation and MMSET) being associated with poor survival in MM [36] . Table S3) . When these parameters were tested together, only STEAP1 and BAALC kept prognostic value. STEAP1 gene expression was also confirmed at protein level in 5 human myeloma cell lines (HMCLs) and purified primary myeloma cells of 5 patients using western blot ( Figure 4A&B ).
Normalized STEAP1 protein expression was significantly correlated with STEAP1
Affymetrix expression (r = .96, P = .01) ( Figure 4A ). STEAP1 gene expression was also Tables S4, S5 and S6). Crossing the gene lists, 4 genes appeared correlated with STEAP1 expression:
dermatan sulfate epimerase (DSE), ubiquitin-conjugating enzyme E2T (UBE2T), atlastin GTPase 3 (ATL3) and CSL-type zinc finger-containing protein 2 (DPH3) (Supplementary Table S7 ). These genes are not linked with a specific biological pathway (Ingenuity and Reactome analyses).
Taken together, these data demonstrate that STEAP1 could be an interesting target not only in solid tumors but also in haematological malignancies. Recent study described a function of STEAP1 in mediating the transfer of small molecules between adjacent cells in culture, indicating its potential role in tumor cell intercellular communication [3] . Antibodies directed to STEAP1 inhibited STEAP1 induced intercellular communication of prostate cancer cells in a dose-dependent manner.
Furthermore, anti STEAP1 antibodies significantly inhibited tumor growth of patient derived prostate and bladder cancer cells in a mouse model [3] . STEAP1 peptides have been recently demonstrated to induce antigen-specific CTLs that were able to recognize and destroy STEAP1-expressing tumor cells in vitro [2, 5] . Active immunization against STEAP1 using DNA prime/modified vaccinia virus Ankara boost strategy inhibits inserm-00760262, version 1 -3 Dec 2012
prostate cancer progression in a murine model [6] . The immunogenicity of STEAP1 has led to the development of anti-STEAP1 antibody-drug conjugates to combine the specificity of anti-STEAP1 antibody to the cytotoxic potency of chemotherapeutic drugs [37] .
Using a dye transfer assay, it was shown that STEAP1 expression in connexin deficient prostate cancer cells induces significant dye transport between cells, which is inhibited by specific STEAP1 siRNA. The predicted secondary structure of STEAP1 as a channel protein supports the possibility that STEAP1 acts as a transporter protein to directly transfer the dye between the cells [3] . More recently, Grunewald et al. demonstrated that STEAP1 is important for anchorage-independent colony-formation and invasiveness of Ewing tumor cells in vitro and for tumorigenicity and metastasis in vivo [34] . In Ewing tumors, STEAP1 expression correlates with increased cellular reactive oxygen species (ROS)-levels, which in turn induce the expression of redox-sensitive and pro-invasive genes. These results sustain previous data that STEAP1 overexpression promotes ROS-mediated hyperproliferation of thyroid epithelial cells [38] . Elevated ROS-levels activate pro-metastatic and pro-proliferative signaling in cancer cells [39, 40] . STEAP1 overexpression could promote proliferation, invasiveness, tumorigenicity, and metastasis through ROS-levels upregulation in cancer. A recent study reported the interest of antibody-drug conjugates as promising therapeutic approach combining the STEAP1 antigen targeting specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic drugs [37] .
Conclusion
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The current analysis emphasizes that STEAP1 could be a good candidate for T-cell based or antibody-based immunotherapy in a large panel of solid and hematological cancers.
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